The progress of immunotherapy for hepatocellular carcinoma
10.3969/j.issn.1000-8179.2019.09.141
- VernacularTitle:肝细胞癌的免疫治疗研究进展
- Author:
Yuhao TANG
1
;
Juncheng WANG
;
Yingqin ZHU
;
Jinbin CHEN
;
Yaojun ZHANG
;
Zhongguo ZHOU
;
Minshan CHEN
;
Li XU
Author Information
1. 中山大学肿瘤防治中心肝胆胰科
- Keywords:
hepatocellular carcinoma (HCC);
immunotherapy;
immune checkpoint inhibitors;
chimeric antigen receptor T cell
- From:
Chinese Journal of Clinical Oncology
2019;46(9):442-447
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma (HCC) accounts for approximately 75%-85% of primary liver cancer cases and is one of the most frequently diagnosed malignancies worldwide. Immunotherapy is currently considered to be the most promising treatment to prevent the progression and postoperative recurrence of HCC. At present, the treatment strategies of immunotherapy for HCC are classified as active immunotherapy and passive immunotherapy, including tumor vaccine therapy, immune checkpoint inhibitors, and adoptive cell therapy. Here we review the current clinical progression and discuss the future perspective on immune therapy for HCC.
